Acadesine inhibits tissue factor induction and thrombus formation by activating the phosphoinositide 3-kinase/akt signaling pathway

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 5, 2010, Pages 1000-1006

  Zhang, Weiyu ^a   Wang, Jianguo ^a   Wang, Huan ^a   Tang, Rong ^a   Belcher, John D ^a   Viollet, Benoit ^b   Geng, Jian Guo ^a   Zhang, Chunxiang ^c   Wu, Chaodong ^d   Slungaard, Arne ^a   Zhu, Chuhong ^a,e   Huo, Yuqing ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b INSERM   (France)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d TEXAS A AND M UNIVERSITY   (United States)

^e THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Anticoagulants; Atherosclerosis; Thrombus; Tissue factor

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; THROMBOPLASTIN; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; CELL STIMULATION; DEEP VEIN THROMBOSIS; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; SIGNAL TRANSDUCTION; THROMBOGENESIS; UMBILICAL VEIN;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD COAGULATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENZYME ACTIVATION; FIBRINOLYTIC AGENTS; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; NF-KAPPA B; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; PYRIMIDINES; RECEPTOR, ADENOSINE A2A; RIBONUCLEOSIDES; RNA, MESSENGER; SEPSIS; SIGNAL TRANSDUCTION; THROMBOPLASTIN; TRANSCRIPTION FACTOR AP-1; TRIAZINES; TRIAZOLES; UP-REGULATION; VENOUS THROMBOSIS;

EID: 77951466092     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.203141     Document Type: Article

References (40)

1. Mangano DT. Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. JAMA. 1997;277:325-332.
2. Mangano DT, Miao Y, Tudor IC, Dietzel C. Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine. J Am Coll Cardiol. 2006;48:206-214.
3. Bullough DA, Zhang C, Montag A, Mullane KM, Young MA. Adeno-sine-mediated inhibition of platelet aggregation by acadesine. A novel antithrombotic mechanism in vitro and in vivo. J ClinInvest. 1994;94: 1524-1532.
4. Dietrich WD, Miller LP, Prado R, Dewanjee S, Alexis N, Dewanjee MK, Gruber H. Acadesine reduces indium-labeled platelet deposition after photothrombosis of the common carotid artery in rats. Stroke. 1995;26: 111-116.
5. Gruber HE, Hoffer ME, McAllister DR, Laikind PK, Lane TA, Schmid-Schoenbein GW, Engler RL. Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granu-locytes, and injury. Circulation. 1989;80:1400-1411.
6. Young MA, Henry C, Wong S, Bullough D, Mullane K. Acadesine reduces the frequency of coronary artery reocclusion following rt-PA induced thrombolysis in the dog. Thromb Haemostat. 1995;74: 1348-1352.
7. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole-4- carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem. 1995;229:558-565.
8. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cell prolif-eration-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol. 2006;574:63-71.
9. Prasad R, Giri S, Nath N, Singh I, Singh AK. 5-aminoimidazole-4- carboxamide-1-beta-4-ribofuranoside attenuates experimental autoimmune encephalomyelitis via modulation of endothelial-monocyte interaction. J Neurosci Res. 2006;84:614-625.
10. Giri S, Nath N, Smith B, Viollet B, Singh AK, Singh I. 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proin-flammatory response in glial cells: a possible role of AMP-activated protein kinase. J Neurosci. 2004;24:479-487.
11. Ayasolla KR, Singh AK, Singh I. 5-aminoimidazole-4-carboxamide-1-beta-4- ribofuranoside (AICAR) attenuates the expression of LPS-and Abeta peptide-induced inflammatory mediators in astroglia. J Neuroin-flammation. 2005;2:21.
12. Nath N, Giri S, Prasad R, Salem ML, Singh AK, Singh I. 5-aminoimidazole-4-carboxamide ribonucleoside: a novel immuno modulator with therapeutic efficacy in experimental autoimmune enceph-alomyelitis. J Immunol. 2005;175:566-574.
13. Morrissey JH, Fakhrai H, Edgington TS. Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell. 1987;50:129-135.
14. Bierhaus A, Zhang Y, Deng Y, Mackman N, Quehenberger P, Haase M, Luther T, Muller M, Bohrer H, Greten J, Martin E, Baeuerlei PA, Waldherr R, Kisiel W, Ziegler R, Stern DM, Nawroth PP. Mechanism of the tumor necrosis factor alpha-mediated induction of endothelial tissue factor. J Biol Chem. 1995;270:26419-26432.
15. Mackman N. Regulation of tissue factor gene expression in human monocytic and endothelial cells. Haemostasis. 1996;26(Suppl 1):17-19.
16. Oeth P, Parry GC, Mackman N. Regulation of the tissue factor gene in human monocytic cells. Role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and lipopolysaccharide-induced expression. Arterioscler Thromb Vasc Biol. 1997;17:365-374.
17. Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem. 2002;277:32124-32132.
18. Schabbauer G, Tencati M, Pedersen B, Pawlinski R, Mackman N. PI3K-Akt pathway suppresses coagulation and inflammation in endo-toxemic mice. Arterioscler Thromb Vasc Biol. 2004;24:1963-1969.
19. Wang J, Mahmud SA, Bitterman PB, Huo Y, Slungaard A. Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes. J Biol Chem. 2007;282:28408-28418.
20. Drew BG, Kingwell BA. Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin Pharmacother. 2008;9:2137-2144.
21. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004;25:33-39.
22. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296: 1655-1657.
23. Martin M, Rehani K, Jope RS, Michalek SM. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol. 2005;6:777-784.
24. Wang H, Tang R, Zhang W, Amirikian K, Geng Z, Geng J, Hebbel RP, Xia L, Marth JD, Fukuda M, Katoh S, Huo Y. Core2 1-6-N-Glucosaminyltransferase-I Is Crucial for the Formation of Atherosclerotic Lesions in Apolipoprotein E-Deficient Mice. Arterioscler Thromb Vasc Biol. 2009;29:180-187.
25. Li YD, Ye BQ, Zheng SX, Wang JT, Wang JG, Chen M, Liu JG, Pei XH, Wang LJ, Lin ZX, Gupta K, Mackman N, Slungaard A, Key NS, Geng JG. NF-kappaB transcription factor p50 critically regulates tissue factor in deep vein thrombosis. J Biol Chem. 2009;284:4473-4483.
26. Fukao T, Koyasu S. PI3K and negative regulation of TLR signaling. Trends Immunol. 2003;24:358-363.
27. Rattan R, Giri S, Singh AK, Singh I. 5-Aminoimidazole-4-carboxamide-1- beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem. 2005;280: 39582-39593.
28. Sengupta TK, Leclerc GM, Hsieh-Kinser TT, Leclerc GJ, Singh I, Barredo JC. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer. 2007;6:46.
29. Nagata D, Takeda R, Sata M, Satonaka H, Suzuki E, Nagano T, Hirata Y. AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation. 2004;110:444-451.
30. Kuo CL, Ho FM, Chang MY, Prakash E, Lin WW. Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cycloox-ygenase-2 gene expression by 5-aminoimidazole-4-carboxamide riboside is independent of AMP-activated protein kinase. J Cell Biochem. 2008; 103:931-940.
31. Morrow VA, Foufelle F, Connell JM, Petrie JR, Gould GW, Salt IP. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem. 2003;278: 31629-31639.
32. Mullane K. Acadesine: the prototype adenosine regulating agent for reducing myocardial ischaemic injury. Cardiovasc Res. 1993;27:43-47. (Pubitemid 23035664)
33. Boison D. Adenosine kinase, epilepsy and stroke: mechanisms and therapies. Trends Pharmacol Sci. 2006;27:652-658.
34. Takasuga S, Katada T, Ui M, Hazeki O. Enhancement by adenosine of insulin-induced activation of phosphoinositide 3-kinase and protein kinase B in rat adipocytes. J Biol Chem. 1999;274:19545-19550.
35. Shen J, Halenda SP, Sturek M, Wilden PA. Cell-signaling evidence for adenosine stimulation of coronary smooth muscle proliferation via the A1 adenosine receptor. Circ Res. 2005;97:574-582.
36. Min KJ, Kim JH, Jou I, Joe EH. Adenosine induces hemeoxygenase-1 expression in microglia through the activation of phosphatidylinositol 3-kinase and nuclear factor E2-related factor 2. Glia. 2008;56: 1028-1037.
37. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993;328:1471-1477.
38. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med. 2003;9:517-524.
39. Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation. 2006;113:722-731.
40. Ren G, Li T, Lan JQ, Wilz A, Simon RP, Boison D. Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control. Exp Neurol. 2007;208:26-37.